Repligen Co. (NASDAQ:RGEN) Shares Sold by Farther Finance Advisors LLC

Farther Finance Advisors LLC cut its stake in Repligen Co. (NASDAQ:RGEN) by 80.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 259 shares of the biotechnology company’s stock after selling 1,060 shares during the quarter. Farther Finance Advisors LLC’s holdings in Repligen were worth $39,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. QRG Capital Management Inc. raised its holdings in Repligen by 31.2% in the 1st quarter. QRG Capital Management Inc. now owns 3,576 shares of the biotechnology company’s stock worth $658,000 after purchasing an additional 850 shares during the period. Russell Investments Group Ltd. raised its stake in shares of Repligen by 5.2% during the 1st quarter. Russell Investments Group Ltd. now owns 35,134 shares of the biotechnology company’s stock worth $6,463,000 after buying an additional 1,746 shares during the period. State Board of Administration of Florida Retirement System raised its stake in shares of Repligen by 4.1% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 64,035 shares of the biotechnology company’s stock worth $10,781,000 after buying an additional 2,520 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in shares of Repligen by 30.2% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 28,883 shares of the biotechnology company’s stock valued at $5,312,000 after buying an additional 6,705 shares in the last quarter. Finally, Nicolet Advisory Services LLC grew its stake in Repligen by 55.4% in the 1st quarter. Nicolet Advisory Services LLC now owns 2,249 shares of the biotechnology company’s stock valued at $409,000 after acquiring an additional 802 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Insider Activity

In related news, Director Anthony Hunt sold 22,191 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the sale, the director now directly owns 139,840 shares of the company’s stock, valued at approximately $20,328,540.80. This trade represents a 13.70 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 1.20% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on RGEN. StockNews.com upgraded shares of Repligen from a “sell” rating to a “hold” rating in a research report on Wednesday. Royal Bank of Canada reiterated an “outperform” rating and set a $205.00 price objective on shares of Repligen in a research note on Thursday, September 26th. Benchmark restated a “hold” rating on shares of Repligen in a research report on Monday, August 5th. Wells Fargo & Company initiated coverage on Repligen in a research report on Tuesday, August 27th. They set an “overweight” rating and a $180.00 price target for the company. Finally, Wolfe Research initiated coverage on Repligen in a report on Thursday. They issued a “peer perform” rating on the stock. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, Repligen presently has an average rating of “Moderate Buy” and an average target price of $190.25.

Repligen Stock Down 5.3 %

Shares of NASDAQ:RGEN opened at $142.43 on Friday. Repligen Co. has a 52-week low of $113.50 and a 52-week high of $211.13. The stock has a market cap of $7.98 billion, a P/E ratio of -389.94, a PEG ratio of 4.27 and a beta of 0.96. The business has a fifty day moving average of $141.59 and a two-hundred day moving average of $144.78. The company has a quick ratio of 5.56, a current ratio of 6.65 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.09. The firm had revenue of $154.87 million during the quarter, compared to analysts’ expectations of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.92%. Repligen’s revenue was up 9.7% compared to the same quarter last year. During the same period last year, the business earned $0.23 earnings per share. On average, research analysts expect that Repligen Co. will post 1.45 earnings per share for the current year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.